Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 8
Submit an article Journal homepage
248
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib

Rossana Maffeia Hematology Division, Department of Oncology and Hematology, A.O.U of Modena-Policlinico, Modena, ItalyCorrespondence[email protected]
View further author information
,
Stefania Fiorcarib Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, ItalyView further author information
,
Claudio Giacinto Ateneb Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, ItalyView further author information
,
Silvia Martinellib Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, ItalyView further author information
,
Lydia Scarfòc Division of Experimental Hematology, Laboratory of B cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, ItalyView further author information
,
Silvia Bonfiglioc Division of Experimental Hematology, Laboratory of B cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, ItalyView further author information
,
Monica Maccaferria Hematology Division, Department of Oncology and Hematology, A.O.U of Modena-Policlinico, Modena, ItalyView further author information
,
Viktor Ljungströmd Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;e Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Patrizia Zucchinib Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, ItalyView further author information
,
Fabio Forghieria Hematology Division, Department of Oncology and Hematology, A.O.U of Modena-Policlinico, Modena, ItalyView further author information
,
Leonardo Potenzab Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, ItalyView further author information
,
Paolo Ghiac Division of Experimental Hematology, Laboratory of B cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, ItalyView further author information
,
Roberto Marascab Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, ItalyView further author information
,
Tommaso Trentif Department of Laboratory Medicine and Pathology, Unità Sanitaria Locale, Modena, ItalyView further author information
,
Enrico Tagliaficog Center for Genome Research, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, ItalyView further author information
&
Mario Luppib Hematology Division, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, ItalyView further author information
 show all
Pages 2018-2021 | Received 05 Oct 2020, Accepted 20 Feb 2021, Published online: 04 Mar 2021

References

  • Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
  • Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
  • O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–1418.
  • Lama TG, Kyung D, O’Brien S. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. Expert Rev Hematol. 2020;13(8):871–883.
  • Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–1443.
  • Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–2294.
  • Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–332.
  • Albitar A, Ma W, DeDios I, et al. Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. Oncotarget. 2017;8(11):17936–17944.
  • Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469–1479.
  • Kanagal-Shamanna R, Jain P, Patel KP, et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019;125(4):559–574.
  • Quinquenel A, Fornecker L-M, Letestu R, et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019;134(7):641–644.
  • Liu T-M, Woyach JA, Zhong Y, et al. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126(1):61–68.
  • Reiff SD, Muhowski EM, Guinn D, et al. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood. 2018;132(10):1039–1049.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.